Search Results - "Guarini, Chiara"

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer by Guarini, Chiara, Grassi, Teresa, Pezzicoli, Gaetano, Porta, Camillo

“…The human epidermal growth factor receptor 2 (HER2) is a well-established oncogenic driver and a successful therapeutic target in several malignancies, such as…”
Get full text

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies by Laface, Carmelo, Maselli, Felicia Maria, Santoro, Anna Natalizia, Iaia, Maria Laura, Ambrogio, Francesca, Laterza, Marigia, Guarini, Chiara, De Santis, Pierluigi, Perrone, Martina, Fedele, Palma

“…Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an activating epidermal growth factor receptor (EGFR) gene mutation. Del19…”
Get full text

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives by Maselli, Felicia Maria, Giuliani, Francesco, Laface, Carmelo, Perrone, Martina, Melaccio, Assunta, De Santis, Pierluigi, Santoro, Anna Natalizia, Guarini, Chiara, Iaia, Maria Laura, Fedele, Palma

“…Prostate cancer (PC) is the most common type of tumor in men. In the early stage of the disease, it is sensitive to androgen deprivation therapy. In patients…”
Get full text

Immunotherapy and Pancreatic Cancer: A Lost Challenge? by Laface, Carmelo, Memeo, Riccardo, Maselli, Felicia Maria, Santoro, Anna Natalizia, Iaia, Maria Laura, Ambrogio, Francesca, Laterza, Marigia, Cazzato, Gerardo, Guarini, Chiara, De Santis, Pierluigi, Perrone, Martina, Fedele, Palma

“…Although immunotherapy has proved to be a very efficient therapeutic strategy for many types of tumors, the results for pancreatic cancer (PC) have been very…”
Get full text

Synergizing Immunotherapy and Antibody-Drug Conjugates: New Horizons in Breast Cancer Therapy by Pinto, Antonello, Guarini, Chiara, Giampaglia, Marianna, Sanna, Valeria, Melaccio, Assunta, Lanotte, Laura, Santoro, Anna Natalizia, Pini, Francesca, Cusmai, Antonio, Giuliani, Francesco, Gadaleta-Caldarola, Gennaro, Fedele, Palma

“…The advent of immunotherapy and antibody-drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However,…”
Get full text

Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside by Fedele, Palma, Santoro, Anna Natalizia, Pini, Francesca, Pellegrino, Marcello, Polito, Giuseppe, De Luca, Maria Chiara, Pignatelli, Antonietta, Tancredi, Michele, Lagattolla, Valeria, Anglani, Alessandro, Guarini, Chiara, Pinto, Antonello, Bracciale, Pietro

“…Lung cancer presents significant therapeutic challenges, motivating the exploration of novel treatment strategies. Programmed cell death (PCD) mechanisms,…”
Get full text

Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response by De Santis, Pierluigi, Perrone, Martina, Guarini, Chiara, Santoro, Anna Natalizia, Laface, Carmelo, Carrozzo, Daniela, Oliva, Gaia Rachele, Fedele, Palma

“…Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis…”
Get full text

Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today? by Perrone, Martina, Giuliani, Francesco, Sanna, Valeria, Bruno, Stefania, Melaccio, Assunta, Santoro, Anna Natalizia, Laface, Carmelo, Maselli, Felicia Maria, Iaia, Maria Laura, Guarini, Chiara, Fancellu, Alessandro, Fedele, Palma

“…Advances in pharmacotherapies that target cell cycle in breast cancer have transformed the therapeutic armamentarium of breast oncology leading to the approval…”
Get more information

Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study by Fedele, Palma, Landriscina, Matteo, Moraca, Lucia, Cusmai, Antonio, Gnoni, Antonio, Licchetta, Antonella, Guarini, Chiara, Lanotte, Laura, Pappagallo, Maria Nicla, Melaccio, Assunta, Giordano, Guido, Maselli, Felicia Maria, Pinto, Antonello, Giuliani, Francesco, Chiuri, Vincenzo, Giotta, Francesco, Gadaleta-Caldarola, Gennaro

“…Metastatic HR+/HER2- breast cancer is commonly treated with CDK4/6 inhibitors in combination with endocrine therapy. However, the efficacy and safety of this…”
Get full text

Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading? by De Santis, Pierluigi, Sanna, Valeria, Perrone, Martina, Guarini, Chiara, Santoro, Anna Natalizia, Laface, Carmelo, Carrozzo, Daniela, Oliva, Gaia Rachele, Fancellu, Alessandro, Fedele, Palma

“…Hormone receptor-positive (HR+) breast cancer (BC) accounts for about 60-70% of all diagnosed BCs, and endocrine therapy has long been the hallmark of systemic…”
Get full text

The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions by Laface, Carmelo, Giuliani, Francesco, Melaccio, Assunta, Pappagallo, Maria Nicla, Santoro, Anna Natalizia, Perrone, Martina, De Santis, Pierluigi, Guarini, Chiara, Carrozzo, Daniela, Fedele, Palma

“…Breast cancer (BC) in elderly women is an increasing health issue due to demographic changes. BC tends to present later and may receive less than standard…”
Get full text